Monogram Biosciences' PhenoSense^® HIV Neutralization, or "Neutralizing Antibody" assay, is available to pharmaceutical and vaccine companies and researchers involved in HIV vaccine, therapeutic antibody research and studies of natural history of infection with HIV. The assay is offered in 3 different formats: HITS, CURVES and CURVES PLUS. HITS is a 4 dilution format used for screening large numbers of plasmas, CURVES format includes a 10 dilution curve that generates IC50s, IC80s, IC90s and IC95s, and the CURVES PLUS offering is the 10 dilution CURVES format plus the percent inhibition of virus at each dilution.

Monogram maintains a large library (virus pools and clones) of HIV-1 envelopes (gp160), including numerous non-subtype B viruses, which allow for virus panel customization. This library includes commonly available lab strain and repository viruses as well as thousands of primary patient isolates. Clients may also send their own viruses (e.g., a vaccine strain) for testing. Monogram Biosciences has recently developed a panel of 20 subtype B viruses from acute/early infection. The antibody neutralization sensitivity, tropism and gp160 sequences have been determined for all isolates. This panel represents currently circulating U.S. viruses and is a Tier 2 Panel for evaluation of sera from candidate vaccines. 

Monogram is also very active in studying the co-evolution of HIV envelope and the antibody response at various stages of infection. Monogram's ability to clone virus envelope directly from any virus source, particularly patient plasma/serum samples allows study of the evolving virus and antibody response in HIV infected patients without the artificial selection inherent in culturing virus or selecting individual clones.   

Click here  to download the Neutralization Brochure.

Related Literature:

Rapid evolution of the neutralizing antibody response to HIV type 1 infection. D. Richman et al; Proc Natl Acad Sci USA. 2003 Apr 1;100(7):4144-9.

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Binley et al; Journal of Virology, 2004 Dec; 78 (23):13232-52.

Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. S. Deeks et al; Journal of Virology, 2006 Jun; 80(12):6155-64.

Neutralizing Antibody Responses Drive the Evolution of Human Immunodeficiency Virus Type 1 Envelope During Recent HIV Infection. S. Frost et al; Proc Natl Acad Sci USA, 102, 18514-9 (2005).

For more information on Monogram assays, services and pricing, please contact us.